Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 extension of zasocitinib for moderately to severely active Crohn's disease or ulcerative colitis
MOH_2026-10-08_017069Phase 2Not yet recruiting
- Sponsor
- Takeda
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zasocitinib in Crohn's disease and autoimmune colitis, sponsored by Takeda. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
zasocitinib
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on MOH_2026-10-08_017069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-10-08_017069.